NIKKEI 225
38,940.25 +452.35 (+1.18%) HANG SENG
18,079.61 0.00 (0.00%) CRUDE OIL
77.37 +0.38 (+0.49%) GOLD FUTURES
2,350.40 +4.60 (+0.20%) DOW
38,686.32 +574.82 (+1.51%) Bitcoin GBP
53,475.00 +290.74 (+0.55%)
Sanofi (SAN1N.MX)
| Previous close | 1,629.20 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 1,629.20 - 1,629.20 |
| 52-week range | 1,609.59 - 1,978.38 |
| Volume | |
| Avg. volume | 722 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | 14.47 |
| EPS (TTM) | 112.62 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswirePress Release: Sanofi launches 2024 global Employee Stock Purchase Plan
Sanofi launches 2024 global Employee Stock Purchase Plan Paris, May 31, 2024. Sanofi’s global employee shareholder plan, Action 2024, opens on June 4, 2024, to around 80,000 employees in 56 countries. Now in its 10th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to secure that employees benefit from the company growth and success. Paul HudsonChief Executive Officer of Sanofi “This plan underscores our ongoing commitment to unite the people of Sanofi b
GlobeNewswireDupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If approved, Dupixent would be the first-ever targeted therapy for COPD in the EU and the first new treatment approach for this disease in more than a decade TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announ
GlobeNewswirePress Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If approved, Dupixent would be the first-ever targeted therapy for COPD in the EU and the first new treatment approach for this disease in more than a decade Paris and Tarrytown, N.Y. May 31, 2024. The European
